Janux Therapeutics (Janux Therapeutics) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Debt-to-Equity?

Janux Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.57 Mil. Janux Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $22.61 Mil. Janux Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $655.76 Mil. Janux Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Janux Therapeutics's Debt-to-Equity or its related term are showing as below:

JANX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.5 Med: 0.07 Max: 0.08
Current: 0.04

During the past 5 years, the highest Debt-to-Equity Ratio of Janux Therapeutics was 0.08. The lowest was -0.50. And the median was 0.07.

JANX's Debt-to-Equity is ranked better than
76.49% of 1076 companies
in the Biotechnology industry
Industry Median: 0.15 vs JANX: 0.04

Janux Therapeutics Debt-to-Equity Historical Data

The historical data trend for Janux Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics Debt-to-Equity Chart

Janux Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.50

0.08

0.07

Janux Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial													0.08	0.08	0.07	0.07	0.04

Competitive Comparison of Janux Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Janux Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Debt-to-Equity falls into.

Janux Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Janux Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.517	+	23.025)	/	344.349
	=	0.07

Janux Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.573	+	22.612)	/	655.763
	=	0.04

Janux Therapeutics (NAS:JANX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Janux Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Janux Therapeutics (Janux Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130

Website

https://www.januxrx.com

Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

Executives

Tighe Reardon	10 percent owner, officer: Acting Chief Financial Officer	C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Avalon Ventures Xi, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Jay Lichter	director, 10 percent owner	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter	officer: Chief Technical Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson	officer: Chief Strategy Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alana B. Mcnulty	director	C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
Ronald W Barrett	director	C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051